-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ProShare Advisors LLC Sells 6,933 Shares of CureVac (NASDAQ:CVAC)
ProShare Advisors LLC Sells 6,933 Shares of CureVac (NASDAQ:CVAC)
ProShare Advisors LLC reduced its holdings in shares of CureVac (NASDAQ:CVAC – Get Rating) by 26.4% during the first quarter, HoldingsChannel.com reports. The fund owned 19,377 shares of the company's stock after selling 6,933 shares during the quarter. ProShare Advisors LLC's holdings in CureVac were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also bought and sold shares of CVAC. Capital Fund Management S.A. bought a new stake in CureVac during the fourth quarter worth $3,452,000. Eversept Partners LP bought a new stake in CureVac during the fourth quarter worth $2,917,000. Bank of America Corp DE lifted its holdings in CureVac by 246.6% during the fourth quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock worth $2,501,000 after acquiring an additional 51,856 shares during the period. Schroder Investment Management Group bought a new stake in CureVac during the fourth quarter worth $1,413,000. Finally, Fosun International Ltd bought a new stake in shares of CureVac in the fourth quarter valued at $337,000.
Get CureVac alerts:Analysts Set New Price Targets
Separately, JMP Securities restated a "buy" rating and issued a $37.00 target price on shares of CureVac in a research note on Thursday, June 9th.
CureVac Stock Down 3.3 %
Shares of CVAC opened at $9.70 on Monday. The stock's fifty day moving average price is $13.14 and its two-hundred day moving average price is $15.71. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.39 and a current ratio of 3.45. CureVac has a 1 year low of $9.35 and a 1 year high of $71.63.CureVac Profile
(Get Rating)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
See Also
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
ProShare Advisors LLC reduced its holdings in shares of CureVac (NASDAQ:CVAC – Get Rating) by 26.4% during the first quarter, HoldingsChannel.com reports. The fund owned 19,377 shares of the company's stock after selling 6,933 shares during the quarter. ProShare Advisors LLC's holdings in CureVac were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.
据HoldingsChannel.com报道,ProShare Advisors LLC在第一季度减持了26.4%的CureVac(纳斯达克代码:CVAC-GET评级)股票。该基金在本季度出售了6933股后,持有该公司19,377股股票。截至ProShare Advisors LLC最近提交给美国证券交易委员会(Securities And Exchange Commission)的文件,该公司持有的CureVac股份价值38万美元。
A number of other hedge funds have also bought and sold shares of CVAC. Capital Fund Management S.A. bought a new stake in CureVac during the fourth quarter worth $3,452,000. Eversept Partners LP bought a new stake in CureVac during the fourth quarter worth $2,917,000. Bank of America Corp DE lifted its holdings in CureVac by 246.6% during the fourth quarter. Bank of America Corp DE now owns 72,885 shares of the company's stock worth $2,501,000 after acquiring an additional 51,856 shares during the period. Schroder Investment Management Group bought a new stake in CureVac during the fourth quarter worth $1,413,000. Finally, Fosun International Ltd bought a new stake in shares of CureVac in the fourth quarter valued at $337,000.
其他一些对冲基金也买卖了CVAC的股票。资本基金管理公司在第四季度购买了价值3,452,000美元的CureVac新股份。Eversept Partners LP在第四季度购买了价值291.7万美元的CureVac新股份。去年第四季度,美国银行(Bank Of America Corp DE)增持CureVac股份246.6%。美国银行DE目前持有72,885股该公司股票,价值2,501,000美元,在此期间又购买了51,856股。施罗德投资管理集团在第四季度购买了价值1,413,000美元的CureVac新股份。最后,复星国际国际有限公司在第四季度购买了价值33.7万美元的CureVac新股。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, JMP Securities restated a "buy" rating and issued a $37.00 target price on shares of CureVac in a research note on Thursday, June 9th.
另外,JMP证券在6月9日星期四的一份研究报告中重申了“买入”评级,并发布了CureVac股票的目标价为37.00美元。
CureVac Stock Down 3.3 %
CureVac股价下跌3.3%
CureVac Profile
CureVac配置文件
(Get Rating)
(获取评级)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.
CureVac N.V.是一家临床阶段的生物制药公司,专注于开发基于信使核糖核酸(MRNA)的各种变革性药物。它正在开发预防疫苗,如处于SARS-CoV-2第一阶段临床试验的mRNA候选疫苗CV2CoV;已完成狂犬病病毒糖蛋白第一阶段临床试验的基于mRNA的预防性疫苗CV7202;处于流感第一阶段临床试验的CVSQIV,以及拉沙热、黄热病、呼吸道合胞病毒、轮状病毒、疟疾和通用流感疫苗。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on CureVac (CVAC)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于CureVac(CVAC)的研究报告
- 随着管理层重组,股市能否迅速反弹?
- MarketBeat:回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖,但仍被高估吗?
Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC – Get Rating).
想看看还有哪些对冲基金持有CVAC吗?访问HoldingsChannel.com获取CureVac(纳斯达克代码:CVAC-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
接受CureVac Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对CureVac和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧